EU industry still unhappy over PV fee burden as legislation nears approval
This article was originally published in Scrip
European industry bodies have generally welcomed last week's compromise deal on the new fees for pharmacovigilance activities, but are disappointed that the fee level for safety referrals is significantly higher than originally proposed by the European Commission. They are also concerned that industry is being asked to share the whole burden of funding the EU's new pharmacovigilance activities.
You may also be interested in...
A legislative provision under which future COVID-19 vaccines can be made available in the UK before they are approved is also being used to offer an unlicensed flu vaccine that officials say has undergone full safety, efficacy and quality tests.
With product shortages made worse by the pandemic, companies in the UK are being asked to use a new system for notifying potential supply disruptions and any plans to discontinue specific medicines.
Two new projects have begun, one on standardizing the assessment of immune responses in individuals vaccinated in clinical trials, the other to improve understanding of potential immunity in patients who have been infected with SARS-CoV-2.